SYS-6036

SYS-6036 is a **humanized monoclonal antibody biosimilar candidate** being developed by **CSPC** for **cancer immunotherapy**. Public company disclosures indicate it was filed in China as a **Class 3.3 therapeutic biologic** and developed according to **biosimilar research guidelines**, with pharmaceutical and nonclinical data reported to show high similarity to the reference product in quality, safety, and efficacy. CSPC's 2025 investor materials place SYS6036 under the **PD-1** program, which strongly suggests it is a **PD-1-targeting checkpoint inhibitor biosimilar** intended for multiple solid tumors, including **melanoma, non-small cell lung cancer, esophageal cancer, head and neck squamous cell carcinoma**, and other tumors listed by commercial pipeline databases. No public INN or reference product name was clearly identified in the accessible primary-source materials reviewed.

Other names

SYS6036 injectionSYS-6036 injectionSYS 6036 injection